Biointron Biological Inc., a CRO company, focused on antibody discovery, recently announced it had raised nearly 500 million RMB ($75M) for Series B funding. Led by more than ten investors, including Co-Stone Venture, Jifeng Ventures, TENYKIN Capital, HAITONG Ventures, Jiangsu Govtor, ALAN AMC, Joy Time, GAORONG Capital, OCTOBER Capital, West Shanghai Group, BEFOR Capital, among others. Prior investors FURONG Capital and CHENGSHU Capital also contributed to this round. The funding will mainly be used for the expansion of CRO service capacity, the production of advanced R&D and manufacturing service lines, and the continued expansion of business development abroad.
Founded in 2012, Biointron is a high-tech enterprise focusing on antibody discovery. The company provides customized services for researching, developing, and producing antibodies as drug candidates. Relying on the industry-leading ultra-high-throughput recombinant protein preparation platform, the company has established various platforms, including single B cell screening, antibody humanization, affinity maturation, VHH library generation, and stable cell line development. Biointron has served thousands of biopharma/biotech companies working on antibody drugs, IVD, vaccines, cell therapies, etc. The company has delivered over 70k+ antibodies for customers’ drug discovery. Biointron will continue to grow and make every effort to provide the best services to customers worldwide and help accelerate the process of antibody discoveries.
The blueprint of Shanghai R&D Center (in plan)
The blueprint of Taizhou Production Center (under construction)